--- title: "Innovent Biologics (1801): news, pipeline and catalysts" url: "https://aibio.space/companies/innovent-biologics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Innovent Biologics news for investors: Innovent Biologics is a Hong Kong-listed Chinese drugmaker that sells 20 medicines in China, including the cancer…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Innovent is profitable at home. IBI363 decides its global story Innovent has become a profitable Chinese drug company with fast sales growth and a large cash pile. Its upside beyond China rests on IBI363 and arcotatug tavatecan, which still need global randomized wins. The balance sheet gives it time to find out. Read the full desk view aibio.space Investor Rank · Opinion **8** /10 Positive view Profitable in China with revenue up 44.8% and over RMB 30 billion in cash; global growth depends on IBI363 and arcotatug tavatecan winning randomized trials. - **Technology**: 2/2 - **Odds**: 1/2 - **Balance sheet**: 2/2 - **Risk**: 1/2 - **Momentum**: 2/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Broad and commercial.** Innovent sells 20 products in China, and its CLDN18.2 drug met a phase 3 endpoint, though its biggest bet, IBI363, has only uncontrolled phase 1 data. - **Odds**: **Mixed by asset.** Arcotatug tavatecan is under priority review in China, while IBI363 must beat docetaxel in a global phase 3 in a setting where many drugs have failed. - **Balance sheet**: **Strong and profitable.** Cash was RMB 30.2 billion at July 31, 2026, and first-half IFRS profit rose 50.2% to RMB 1,253.1 million. - **Main risk**: **Global proof is pending.** The large partner deals pay mostly in milestones, and IBI363 carries a 64.9% rate of grade 3 or worse side effects at its higher dose. - **Watch next**: **ESMO and melanoma.** Gastric cancer phase 3 data come at ESMO on October 23, and the IBI363 melanoma readout is due by early 2027. ## Top news on Innovent ## Dates **October 23, 2026** G-HOPE-001 phase 3 data for arcotatug tavatecan in gastric cancer as an ESMO late-breaking abstract (LBA77) [Source](https://www.prnewswire.com/news-releases/innovent-to-present-new-clinical-data-of-next-gen-io-and-adc-pipeline-at-the-2026-esmo-annual-meeting-302887455.html) **End of 2026 to early 2027** Data readout and possible China NDA for IBI363 in melanoma [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) **Second half of 2026** Start of global phase 3 trials of IBI324 in DME and wet AMD by partner Ollin [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) **By end of 2026** Planned NDA submissions for efdamrofusp alfa (wet AMD) and tafolecimab (first-line hypercholesterolemia) [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) ## The money Cash on hand of RMB 30.2 billion (about US$4.5 billion) as of July 31, 2026. No runway guidance; the company is profitable. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) First half 2026 total revenue RMB 8,617.8 million (up 44.8%), product revenue RMB 8,201.5 million (up 56.7%), IFRS profit RMB 1,253.1 million. Innovent reports half-yearly. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) ## Risks on the record - IBI363 caused grade 3 or worse treatment-emergent adverse events in 64.9% of patients at 3 mg/kg in its lung cancer phase 1 study. [Source](https://www.prnewswire.com/news-releases/2026-asco--innovent-presents-long-term-follow-up-results-from-the-poc-study-of-ibi363-tak-928-pd-1il-2-bias-bispecific-fusion-protein-showing-robust-survival-benefits-in-advanced-immunotherapy-resistant-non-small-cell-lung-302786450.html) - Gross margin slipped to 85.0% from 86.0% as R&D spending rose to RMB 1,683.7 million from RMB 1,008.8 million in the first half of 2026. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) - Global value of the lead assets is shared: Takeda holds ex-China rights to arcotatug tavatecan and co-develops IBI363, selling it alone outside the U.S. and Greater China. [Source](https://www.prnewswire.com/news-releases/innovent-announces-expansion-of-global-phase-3-marslight-11-study-of-ibi363tak-928-alpha-biased-il-2pd-1-bispecific-fusion-protein-in-immunotherapy-resistant-nsclc-to-include-patients-with-non-squamous-nsclc-302890858.html) ## Questions investors ask ### What is aibio.space's Investor Rank for Innovent Biologics? 8 out of 10, our positive view. Profitable in China with revenue up 44.8% and over RMB 30 billion in cash; global growth depends on IBI363 and arcotatug tavatecan winning randomized trials. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### Is Innovent Biologics profitable? Yes. Innovent reported IFRS profit of RMB 1,253.1 million for the first half of 2026, up 50.2%, after its first full-year profit in 2025. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) ### What is IBI363? IBI363 is a PD-1 blocker fused to an IL-2 arm biased toward the alpha receptor. It is in the global phase 3 MarsLight-11 trial against docetaxel in lung cancer that progressed after immunotherapy, co-developed with Takeda. [Source](https://www.prnewswire.com/news-releases/innovent-announces-expansion-of-global-phase-3-marslight-11-study-of-ibi363tak-928-alpha-biased-il-2pd-1-bispecific-fusion-protein-in-immunotherapy-resistant-nsclc-to-include-patients-with-non-squamous-nsclc-302890858.html) ### How much cash does Innovent have? Innovent had cash on hand of RMB 30.2 billion, about US$4.5 billion, as of July 31, 2026. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) ### What is arcotatug tavatecan? It is Innovent's CLDN18.2-targeted antibody-drug conjugate, also called IBI343 or TAK-921. Its phase 3 G-HOPE-001 trial in previously treated gastric cancer met its primary endpoint and the China filing was accepted with priority review. [Source](https://www.prnewswire.com/news-releases/worlds-first-cldn18-2-adc-for-regulatory-review-innovent-biologics-announces-ibi343-arcotatug-tavatecan-met-primary-endpoint-in-international-phase-3-study-in-advanced-refractory-gastric-cancer-and-nda-accepted-by-china-nmpa-302791220.html) ### Who is Innovent's CEO? Dr. De-Chao Michael Yu is Innovent's founder, chairman and chief executive officer, and holds both the chairman and CEO roles. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) ### Where is Innovent Biologics headquartered? SEC records list its business address as 120 BROADWAY, NEW YORK, NY, 10271. Source ## Legal and investor matters Checked against Innovent Biologics filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. The 2025 annual report (published 2026-04-28) states: "The Company was not involved in any material litigation or arbitration during the year ended 31 December 2025." The 2026 interim report (published 2026-09-29) states the same for the six months ended 30 June 2026. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf) 1. 2026-05-29 Other Innovent signs oncology collaboration with Pfizer, US$650 million upfront On 2026-05-29 Innovent Biologics announced a global licensing and collaboration agreement with Pfizer covering 12 early-stage oncology programs, including antibody-drug conjugates and multi-specific antibodies. Innovent will receive a US$650 million upfront payment and is eligible for up to US$9.85 billion in milestones, for a total value of up to US$10.5 billion, plus royalties. Closing is subject to required regulatory approvals. [HKEXnews announcement, Innovent Biologics, Inc.](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0529/2026052900029.pdf) 2. 2026-02-08 Other Innovent signs Lilly collaboration with US$350 million upfront On 2026-02-08 Innovent Biologics announced a strategic collaboration with Eli Lilly in oncology and immunology, with a US$350 million upfront payment and milestones of up to about US$8.5 billion. The agreement became effective on 2026-03-24 after early clearance from the U.S. Federal Trade Commission. Innovent said on 2026-03-25 that media reports describing the effectiveness as an acquisition of the company were incorrect and that it was not pursuing such a transaction. [HKEXnews announcement, Innovent Biologics, Inc.](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0208/2026020800009.pdf) 3. 2025-12-04 Financing Innovent issues 6,913,834 shares to Takeda at HK$112.56 as Takeda deal closes On 2025-12-04 Innovent Biologics closed a share issuance to Takeda Pharmaceuticals International under its general mandate, allotting 6,913,834 shares at HK$112.56 per share, about 0.40% of the enlarged share capital. Gross proceeds were about HK$778 million. The issue was part of a collaboration announced on 2025-10-22 that carries a US$1.2 billion upfront payment including a US$100 million equity investment. [HKEXnews announcement, Innovent Biologics, Inc.](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1205/2025120500041.pdf) 4. 2025-06-26 Financing Innovent places 55,000,000 new shares at HK$78.36, with net proceeds of about HK$4.27 billion On 2025-06-26 Innovent Biologics agreed to place 55,000,000 new shares at HK$78.36 per share under its general mandate, about 3.33% of shares in issue. Net proceeds were about HK$4,265.4 million. The placing completed on 2025-07-04, with shares placed to not fewer than six independent placees. [HKEXnews announcement, Innovent Biologics, Inc.](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0626/2025062600057.pdf) 5. 2025-01-16 Other Innovent says it knows of no inside information after unusual share movement On 2025-01-16 Innovent Biologics issued a voluntary announcement saying it had noted unusual price and trading volume movements in its shares. After reasonable enquiries, the board said it was not aware of any information that needed to be disclosed to avoid a false market, or any inside information under the Securities and Futures Ordinance. The company said its business and operations remained unchanged. [HKEXnews announcement, Innovent Biologics, Inc.](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0116/2025011600992.pdf) 6. 2025-01-02 Other Innovent grants Roche global rights to DLL3 ADC IBI3009 for US$80 million upfront On 2025-01-02 Innovent Biologics announced a collaboration and exclusive license agreement with Roche for IBI3009, a DLL3-targeted antibody-drug conjugate for small cell lung cancer. Roche receives exclusive global rights to develop, manufacture and commercialize it. Innovent will receive an upfront payment of US$80 million and is eligible for milestone payments of up to US$1 billion plus tiered royalties. [HKEXnews announcement, Innovent Biologics, Inc.](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0102/2025010200009.pdf) ## Pipeline | Program | Indication | Stage | |---|---|---| | IBI363 (TAK-928, PD-1/IL-2α-biased bispecific) | Immunotherapy-resistant squamous and non-squamous NSCLC; melanoma; colorectal cancer | Global phase 3 (MarsLight-11) with Takeda; China registrational melanoma study [Source](https://www.prnewswire.com/news-releases/innovent-announces-expansion-of-global-phase-3-marslight-11-study-of-ibi363tak-928-alpha-biased-il-2pd-1-bispecific-fusion-protein-in-immunotherapy-resistant-nsclc-to-include-patients-with-non-squamous-nsclc-302890858.html) | | Arcotatug tavatecan (IBI343/TAK-921, CLDN18.2 ADC) | Third-line CLDN18.2-positive gastric or gastroesophageal junction cancer; pancreatic cancer | NDA under NMPA priority review (accepted June 2026); phase 3 in pancreatic cancer [Source](https://www.prnewswire.com/news-releases/worlds-first-cldn18-2-adc-for-regulatory-review-innovent-biologics-announces-ibi343-arcotatug-tavatecan-met-primary-endpoint-in-international-phase-3-study-in-advanced-refractory-gastric-cancer-and-nda-accepted-by-china-nmpa-302791220.html) | | Mazdutide (GCG/GLP-1 dual agonist) | Weight management and type 2 diabetes | Approved in China; 9 mg weight management NDA under review [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) | | IBI324 (VEGF/ANG2) | Diabetic macular edema and wet AMD | Global phase 3 planned by partner Ollin in second half of 2026 [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) | | IBI3003 (GPRC5D/BCMA/CD3 trispecific) | Relapsed or refractory multiple myeloma | Phase 3 in China (first patient dosed June 2026); phase 1 in U.S. [Source](https://www.prnewswire.com/news-releases/2026-ims-oral-presentation-innovent-announces-updated-phase-1-clinical-data-of-trispecific-antibody-ibi3003-gprc5dbcmacd3-in-patients-with-relapsed-or-refractory-multiple-myeloma-302892611.html) | | SYCUME (teprotumumab N01, IGF-1R) | Thyroid eye disease, including inactive disease | Approved in China; phase 3 RESTORE-3 in inactive TED met primary endpoint [Source](https://www.prnewswire.com/news-releases/innovent-announces-phase-3-restore-3-study-of-sycume-teprotumumab-n01-injection-met-primary-endpoint-in-inactive-thyroid-eye-disease-302902606.html) | ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open HKEX:1801 on TradingView](https://www.tradingview.com/symbols/HKEX-1801/). ## SEC filings and registration - **SEC name**: Innovent Biologics Inc/ADR - **CIK**: 1774163 - **US tickers**: IVBXF (OTC) - **Business address**: 120 BROADWAY, NEW YORK, NY, 10271 - **Phone**: 212-238-3000 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001774163), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/innovent-biologics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Innovent Biologics (1801): news, pipeline and catalysts", 2026-10-31, https://aibio.space/companies/innovent-biologics/